• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗心律失常药物:风险与收益。

Antiarrhythmic Drugs: Risks and Benefits.

机构信息

Department of Cardiology, Virginia Commonwealth University Health System, PO Box 980053, Richmond, VA 23235, USA.

Department of Electrophysiology, Virginia Commonwealth University Health System, PO Box 980053, Richmond, VA 23235, USA.

出版信息

Med Clin North Am. 2019 Sep;103(5):821-834. doi: 10.1016/j.mcna.2019.05.004. Epub 2019 Jul 6.

DOI:10.1016/j.mcna.2019.05.004
PMID:31378328
Abstract

The narrow therapeutic window of antiarrhythmic drugs makes their use clinically challenging. A solid understanding of the mechanisms of arrhythmias and how antiarrhythmics affect these mechanisms is only a preliminary step in their appropriate selection. Clinical factors, side-effect profiles, and proarrhythmic risks are more important than the cellular mechanisms of actions in drug selection and monitoring. This article provides a simplified approach to understanding cellular mechanisms and provides a practical approach to the selection and use of this important class of medications.

摘要

抗心律失常药物的治疗窗狭窄,使其在临床上的应用具有挑战性。深入了解心律失常的机制以及抗心律失常药物如何影响这些机制,只是正确选择药物的初步步骤。在药物选择和监测中,临床因素、副作用特征和致心律失常风险比药物作用的细胞机制更为重要。本文提供了一种简化理解细胞机制的方法,并提供了一种实用的方法来选择和使用这一重要类别的药物。

相似文献

1
Antiarrhythmic Drugs: Risks and Benefits.抗心律失常药物:风险与收益。
Med Clin North Am. 2019 Sep;103(5):821-834. doi: 10.1016/j.mcna.2019.05.004. Epub 2019 Jul 6.
2
Pharmacotherapy of cardiac arrhythmias--basic science for clinicians.心律失常的药物治疗——临床医生的基础科学
Pacing Clin Electrophysiol. 2009 Nov;32(11):1454-65. doi: 10.1111/j.1540-8159.2009.02526.x. Epub 2009 Sep 10.
3
Are antiarrhythmic drugs safe?
Clin Cardiol. 1990 Jul;13(7):491-6. doi: 10.1002/clc.4960130712.
4
Pharmacologic management of arrhythmias in patients with congenital heart disease.先天性心脏病患者心律失常的药物治疗
Am J Cardiovasc Drugs. 2001;1(2):91-103. doi: 10.2165/00129784-200101020-00003.
5
Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs.抗心律失常药物促心律失常机制的实验证据。
Cardiovasc Res. 1998 Mar;37(3):567-77. doi: 10.1016/s0008-6363(97)00293-9.
6
Clinical pharmacology of antiarrhythmic drugs: variability of metabolism and dose requirements.抗心律失常药物的临床药理学:代谢变异性与剂量需求
J Cardiovasc Pharmacol. 1991;17 Suppl 6:S74-6.
7
Managing geriatric arrhythmias, II: Drug selection and use.老年心律失常的管理,II:药物选择与应用
Geriatrics. 1991 Apr;46(4):41-4, 49-52, 54.
8
Perioperative Management of Beta Blockers and Other Antiarrhythmic Medications.β受体阻滞剂及其他抗心律失常药物的围手术期管理
Curr Clin Pharmacol. 2017;12(3):141-144. doi: 10.2174/1574884712666170829114820.
9
Ventricular arrhythmias: mechanisms and actions of antiarrhythmic drugs.室性心律失常:抗心律失常药物的机制与作用
Am Heart J. 1984 May;107(5 Pt 2):1053-7. doi: 10.1016/0002-8703(84)90174-1.
10
Can antiarrhythmic drugs survive survival trials?抗心律失常药物能否在生存试验中留存?
Am J Cardiol. 1998 Mar 19;81(6A):24D-34D. doi: 10.1016/s0002-9149(98)00150-7.

引用本文的文献

1
Molecular mechanisms and intervention approaches of heart failure (Review).心力衰竭的分子机制及干预方法(综述)
Int J Mol Med. 2025 Aug;56(2). doi: 10.3892/ijmm.2025.5566. Epub 2025 Jun 13.
2
Administration with ameliorates the progression of atrial fibrillation by affecting atrial remodeling and oxidative stress via the activation of the PI3K/AKT signaling.通过激活PI3K/AKT信号通路影响心房重构和氧化应激,[药物名称]给药可改善心房颤动的进展。
Cytotechnology. 2025 Jun;77(3):121. doi: 10.1007/s10616-025-00778-8. Epub 2025 Jun 9.
3
Clinical Outcomes of Intracardiac Echocardiography-Guided Radiofrequency Catheter Ablation for Atrial Fibrillation: A Retrospective Study.
心腔内超声引导下射频导管消融治疗心房颤动的临床结果:一项回顾性研究
Echocardiography. 2025 Feb;42(2):e70096. doi: 10.1111/echo.70096.
4
Novel Electroactive Therapeutic Platforms for Cardiac Arrhythmia Management.用于心律失常管理的新型电活性治疗平台。
Adv Sci (Weinh). 2025 Jun;12(24):e2500061. doi: 10.1002/advs.202500061. Epub 2025 Feb 14.
5
Shensong yangxin, a multi-functional traditional Chinese medicine for arrhythmia: A review of components, pharmacological mechanisms, and clinical applications.参松养心——一种用于治疗心律失常的多功能中药:成分、药理机制及临床应用综述
Heliyon. 2024 Aug 2;10(16):e35560. doi: 10.1016/j.heliyon.2024.e35560. eCollection 2024 Aug 30.
6
Mechanism of Guigan Longmu Decoction in the Treatment of Arrhythmias Based on Network Pharmacology and Untargeted Metabolomics Assays.基于网络药理学和非靶向代谢组学分析的归肝龙牡汤治疗心律失常的机制
Comb Chem High Throughput Screen. 2025;28(8):1384-1401. doi: 10.2174/0113862073293313240519161145.
7
Drugs associated with a risk of supraventricular tachycardia: analysis using the OpenVigil database.与室上性心动过速风险相关的药物:使用 OpenVigil 数据库进行分析。
J Int Med Res. 2024 Mar;52(3):3000605241238993. doi: 10.1177/03000605241238077.
8
Vascular Endothelial Barrier Protection Prevents Atrial Fibrillation by Preserving Cardiac Nanostructure.血管内皮屏障保护通过维持心脏纳米结构预防心房颤动。
JACC Clin Electrophysiol. 2023 Dec;9(12):2444-2458. doi: 10.1016/j.jacep.2023.10.013. Epub 2023 Nov 29.
9
Tic-Tac: A Translational Approach in Mechanisms Associated with Irregular Heartbeat and Sinus Rhythm Restoration in Atrial Fibrillation Patients.Tic-Tac:心房颤动患者与不规则心跳和窦性节律恢复相关的机制的转化方法。
Int J Mol Sci. 2023 Aug 16;24(16):12859. doi: 10.3390/ijms241612859.
10
Novel Arylpiperazine Derivatives of Salicylamide with α-Adrenolytic Properties Showed Antiarrhythmic and Hypotensive Properties in Rats.新型芳基哌嗪水杨酰胺衍生物具有α-肾上腺素能阻滞特性,在大鼠中表现出抗心律失常和降压作用。
Int J Mol Sci. 2022 Dec 24;24(1):293. doi: 10.3390/ijms24010293.